Google
Trusted Resources: News & Meetings
Latest announcements and gatherings
Acoramidis Reduces All-Cause, Cardiovascular Mortality at 30 Months in ATTR-CM
The 30-month results of the phase 3 ATTRibute-CM trial provide the latest insight into the effects of acoramidis in people with transthyretin amyloid cardiomyopathy (ATTR-CM) ahead of a potential regulatory submission for the agent.
Presented during a hot line session at the European Society of Cardiology (ESC) Congress 2023, results of the trial suggest the acoramidis cohort experienced an 81% survival rate at 30 months, with additional analysis suggesting use of acoramidis was associated with a 30% reduction in risk of cardiovascular death relative to placebo therapy.1
myBinderRelated Content
-
San Diego — Amyloidosis Support Groups Meeting — LIVE — Saturday, April 27, 2024When: Saturday, April 27, 2024 AL wi...
-
From older to younger: intergenerational promotion of health behaviours in Portuguese families affected by familial ...The role of older generations in familie...
-
Rodney H. Falk, MDDr. Rodney H. Falk is the Director of th...
-
Eplontersen halted ATTRv-PN disease progression and improved neuropathy impairment and quality of life in Phase 3 st...CARLSBAD, Calif., April 24, 2023 /PRNe...
-
From older to younger: intergenerational promotion of health behaviours in Portuguese families affected by familial ...What is this summary about? This is a p...
-
Ronald G. Schwartz, MD, MSDr. Schwartz is a Professor of Medicin...
-
Richard B. Stacey, MDDr. Richard B. Stacey is a cardiologist ...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences.
More information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Community Key Collaborator
Support for this landing page is provided by an independent education grant from
Translation of this platform made possible through an independent education grant from
Powered by
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences.
More information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
